Logo

Tekmira Sells Additional Stock to Offering Underwriters

Nov 07, 2013
Premium

Tekmira Pharmaceuticals this week said that the underwriters of its recent public stock offering of 3.75 million shares have exercised their over-allotment option to buy an additional 562,000 shares at $8 apiece.

With the additional stock sold, Tekmira raised a total of about $34.5 million in the transaction.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Tekmira
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.